End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants, strengthening the case for a novel...
Hence then, the article about brii bio presents late breaking data from its ongoing phase 2 ensure study at easl congress 2025 suggesting brii 179 s role in advancing higher hbsag loss was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss )
Also on site :
- Greg Evigan Shares Sweet ‘My Two Dads’ Throwback With Paul Reiser and Staci Keanan: ‘I Adore These 2 People!’
- Carole King Wrote ‘Will You Love Me Tomorrow’ at 18 and It Became the First No. 1 Song by Any Girl Group; She Sang It 11 Years Later on Tapestry
- Aaron Sorkin Says Jeremy Strong Treated His Co-Stars ‘The Way He Imagines’ Mark Zuckerberg Treats People While Shooting ‘The Social Reckoning’